<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00514683</url>
  </required_header>
  <id_info>
    <org_study_id>1199.30</org_study_id>
    <nct_id>NCT00514683</nct_id>
  </id_info>
  <brief_title>Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>A 12 Month, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of BIBF 1120 Administered at Oral Doses of 50 mg qd, 50 mg Bid, 100 mg Bid and 150 mg Bid on Forced Vital Capacity Decline During One Year, in Patients With Idiopathic Pulmonary Fibrosis, With Optional Active Treatment Extension Until Last Patient Out.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The general purpose of this trial is to investigate the efficacy and safety of 4 dose
      strategies of BIBF 1120 treatment for 12 months, compared to placebo in patients with
      idiopathic pulmonary fibrosis.

      The primary objective of this study is to demonstrate whether at least one dose strategy is
      superior to placebo in patients with IPF, in modifying the rate of decline of Forced Vital
      Capacity (FVC).

      As a secondary objective, additional parameters will be assessed in order to differentiate
      between dose strategies on the basis of safety and efficacy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Decline in FVC</measure>
    <time_frame>Baseline until 52 weeks</time_frame>
    <description>Rate of decline in Forced Vital Capacity (FVC) evaluated from baseline until 52 weeks of treatment.
The means presents actually the adjusted rate based on a MMRM with fixed terms for treatment*time, gender*height, gender*age and random terms for patient effect, patient*time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in FVC%Pred</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Change from baseline in percentage of predicted Forced Vital Capacity (FVC%pred) at 52 weeks.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline and region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in FVC</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Change from baseline in percentage of absolute Forced Vital Capacity (FVC) at 52 weeks.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline and region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change From Baseline in FVC%Pred</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Percent change from baseline in percentage of predicted Forced Vital Capacity (FVC%pred) at 52 weeks.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline and region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change From Baseline in FVC</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Percent change from baseline in absolute Forced Vital Capacity (FVC) at 52 weeks.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline and region</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in FVC by Categories</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Change from baseline in percentage of Forced Vital Capacity (FVC) at 52 weeks in below mentioned categories:
Decrease &gt; 10% or 200mL
Change within &lt;= 10% or &lt;=200 mL
Increase &gt; 10% or 200mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival (All Causes of Death and Lung-transplant Free)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Survival (all causes of death and lung-transplant free) at 52 weeks, based on overall mortality and on-treatment survival.
Failure means participants with event and Censored means participants with no event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in SpO2 at Rest</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Absolute change from baseline in oxygen saturation (SpO2) at rest.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in SpO2 at Rest by Categories</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Absolute change from baseline in oxygen saturation (SpO2) at rest by below mentioned categories:
SpO2 (non-invasive) at 52 weeks:
Decrease &gt; 4% SpO2
Change within +/- 4% SpO2
Increase &gt; 4% SpO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in PaO2</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Absolute change from baseline in Arterial oxygen partial pressure (PaO2) at week 52. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in P(A-a)O2</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Absolute change from baseline in Alveolo-arterial oxygen gradient (P(A-a)O2) at week 52. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in PaCO2</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Absolute change from baseline in Arterial carbon dioxyde partial pressure (PaCO2) at week 52. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in PaO2 by Categories</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Absolute change from baseline in Arterial oxygen partial pressure (PaO2) by below mentioned categories:
Decrease &gt; 4 mmHg
Change within +/- 4 mmHg
Increase &gt; 4 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in P(A-a) O2 by Categories</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Absolute change from baseline in Alveolo-arterial oxygen gradient (P(A-a) O2) by below mentioned categories:
Decrease &gt; 4 mmHg
Change within +/- 4 mmHg
Increase &gt; 4 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in DLCO</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Absolute change from Baseline in Diffusing capacity of the lung for carbon monoxide (DLCO) at 52 weeks.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in DLCO by Categories</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Absolute change from baseline in Diffusing capacity of the lung for carbon monoxide (DLCO) by below mentioned categories:
Decrease &gt; 15% or &gt; 1
Change &lt;= 15% or &lt;= 1
Increase &gt; 15% or &gt; 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Distance Walk (6-MWT)</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Absolute change from baseline in distance walk (6-MWT) at 52 weeks. The 6-Minutes Walk Test (6-MWT) was conducted according to the American Thoracic Society (ATS) Criteria. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Dyspnoea Rating on Borg Scale Before Exercise (6-MWT)</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Absolute change from baseline in Dyspnoea rating before exercise (6-MWT) at 52 weeks based on Borg scale as mentioned below :
0: Nothing at all, 0.5: Very, very slight (just noticable), 1: Very slight, 2: Slight (light), 3: Moderate, 4: Somewhat severe, 5: Severe (heavy), 6, 7:Very severe, 8, 9, 10: Very, very severe (Maximal).
The 6-Minutes Walk Test (6-MWT) was conducted according to the ATS Criteria. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dyspnoea Rating on Borg Scale After Exercise (6-MWT)</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Change from baseline in Dyspnoea rating after exercise (6-MWT) at 52 weeks based on Borg scale as mentioned below :
0: Nothing at all, 0.5: Very, very slight (just noticable), 1: Very slight, 2: Slight (light), 3: Moderate, 4: Somewhat severe, 5: Severe (heavy), 6, 7:Very severe, 8, 9, 10: Very, very severe (Maximal).
The 6-Minutes Walk Test (6-MWT) was conducted according to the ATS Criteria. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in MRC Dyspnea Scale by Categories</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Absolute change from baseline in Medical Research Council (MRC) dyspnea scale by below mentioned categories:
Decrease
No Change
Increase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in FEV1/FVC</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Change from baseline of percentage of FVC expelled in the first second of a forced expiration (FEV1/FVC) at 52 weeks.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SGRQ Total Score</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Change from baseline in Saint George's Respiratory Questionnaire (SGRQ) total score. Total score is defined as sum of the three domain scores symptoms, activities and impacts. Scores range from 0 to 100, with higher scores indicating worst possible health status.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SGRQ Domain Score Symptoms</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Change from baseline in Saint George's Respiratory Questionnaire (SGRQ) domain score symptoms. Scores range from 0 to 100, with higher scores indicating more limitations.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SGRQ Domain Score Impacts</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Change from baseline in Saint George's Respiratory Questionnaire (SGRQ) domain score impacts. Scores range from 0 to 100, with higher scores indicating worst possible health status.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Domain Score Activities</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Change from baseline in Saint George's Respiratory Questionnaire (SGRQ) domain score activities. Scores range from 0 to 100, with higher scores indicating worst possible health status.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St George's Respiratory Questionnaire (SGRQ) Responder</measure>
    <time_frame>52 weeks</time_frame>
    <description>St George's Respiratory Questionnaire (SGRQ) responder (&lt;= -4 points change) (%) at 52 weeks-worst case</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TLC</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Change from Baseline in Total Lung Capacity (TLC) at 52 weeks. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in RV</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Change from Baseline in Residual volume (RV) at 52 weeks. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in TGV</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Change from Baseline in Thoracic gas volume (TGV) at 52 weeks. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in VC</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Change from baseline in Vital capacity (VC) at 52 weeks. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in IC</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Change from Baseline in Inspiratory Capacity (IC) at 52 weeks. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With at Least One IPF Exacerbation</measure>
    <time_frame>52 weeks</time_frame>
    <description>Number of patients with at least one Idiopathic Pulmonary Fibrosis (IPF) exacerbation at 52 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrences of IPF Exacerbations Per Patient Per Year</measure>
    <time_frame>52 weeks</time_frame>
    <description>Occurrences of Idiopathic Pulmonary Fibrosis (IPF) exacerbations per patient per year at 52 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of IPF Exacerbation</measure>
    <time_frame>52 weeks</time_frame>
    <description>This endpoint is called time to first occurrence of IPF exacerbation however it was actually analysed as the proportion of patients having occurrence of Idiopathic Pulmonary Fibrosis (IPF) exacerbation at 52 weeks.
Failure means participants with event and Censored means participants with no event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival (Death Due to Respiratory Cause, and Lung-transplant Free)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Survival (death due to respiratory cause, and lung-transplant free) at 52 weeks.
Failure means participants with event and Censored means participants with no event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>52 weeks</time_frame>
    <description>Time to progression. Progression was defined as at least one of the following: 5mmHg increase in the alveolo-arterial pressure difference in oxygen (P(A-a)O2), 10% decrease in FVC (FVC(baseline)-FVC(progression) &gt;= 10%) or Death.
Failure means participants with event and Censored means participants with no event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose Plasma Concentration of Nintedanib in Plasma at Steady State on Day 365 (Cpre,ss,365) and Day 729 (Cpre,ss,729).</measure>
    <time_frame>day 365 and day 729</time_frame>
    <description>Cpre,ss,729 represents the pre-dose plasma concentration of nintedanib in plasma at steady state on Day 729 and Cpre,ss,365 represents the pre-dose plasma concentration of nintedanib in plasma at steady state on Day 365. At day 365, values only for Nintedanib 50 qd group are presented as no values reported for other groups and at day 729, values are presented for all group except for Nintedanib 50 qd group as no values reported for it.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">432</enrollment>
  <condition>Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose BIBF1120 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose BIBF 1120 twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intermediate dose BIBF 1120 twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose BIBF 1120 twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose BIBF1120 once daily</intervention_name>
    <description>low dose BIBF1120 once daily</description>
    <arm_group_label>dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose BIBF 1120 twice daily</intervention_name>
    <description>low dose BIBF 1120 twice daily</description>
    <arm_group_label>dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intermediate dose BIBF 1120 twice daily</intervention_name>
    <description>intermediate dose BIBF 1120 twice daily</description>
    <arm_group_label>dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose BIBF 1120 twice daily</intervention_name>
    <description>high dose BIBF 1120 twice daily</description>
    <arm_group_label>dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient &gt;40 years

          2. Written informed consent signed prior to entry into the study

          3. IPF diagnosed (according to ATS / ERS criteria) less than 5 years prior to screening
             visit.

          4. HRCT within 12 months of randomisation and biopsy (the latter if needed to fulfil
             ATS/ERS criteria) centrally reviewed and consistent with diagnosis.

          5. FVC&gt;50 % of predicted value

             Predicted normal values will be calculated according to ESCS (R94-1408):

             Males :

             FVC predicted (L) = 5.76 x height (meters)- 0.026 x age (years) -4.34

             Females :

             FVC predicted (L) = 4.43 x height (meters)- 0.026 x age (years) -2.89

          6. Single breath DLCO (corrected for Hb) 30 - 79% inclusive of predicted .

             Different sites may use different prediction formulas, based on the method used to
             measure DLco. In any case, the method used must be in compliance with the ATS/ERS
             guideline on DLCO measurements (R06-2002), and the prediction formula appropriate for
             that method. Raw data (gas mixture, equation used for prediction of normal, further
             adjustments made if so) must be traced.

             Adjustment for haemoglobin (R06-2002):

             Males :

             DLCO predicted for Hb = DLCO predicted x (1.7Hb/[10.22+Hb])

             Females :

             DLCO predicted for Hb = DLCO predicted x (1.7Hb/[9.38+Hb]) where Hb is expressed in
             g/dL-1

          7. PaO2 &gt;= 55 mmHg (sea level to 1500 m) or 50 mmHg (above 1500 m) room air

        Exclusion Criteria:

          1. AST, ALT &gt; 1.5 x ULN ;

          2. Bilirubin &gt; 1.5 x ULN

          3. Relevant airways obstruction

          4. Continuous oxygen supplementation at randomisation (defined as &gt; 15 hours supplemental
             oxygen per day).

          5. Active infection at screening or randomisation.

          6. Neutrophils &lt; 1500 / mm3

          7. International normalised ratio (INR) &gt; 1.5 and/or Partial thromboplastin time (PTT) &gt;
             1.5 x ULN ;

          8. Platelets &lt; 100 000 /mL

          9. Haemoglobin &lt; 9.0 g/dL

         10. In the opinion of the Investigator, patient is likely to have lung transplantation
             during study

         11. Life expectancy for disease other than IPF &lt; 2.5 years (Investigator assessment).

         12. Other disease that may interfere with testing procedures or in judgement of
             Investigator may interfere with trial participation or may put the patient at risk
             when participating to this trial.

               -  Myocardial infarction during the previous 6 months

               -  Unstable angina during the previous month

         13. Other investigational therapy received within 8 weeks prior to screening visit.

         14. Pregnant women or women who are breast feeding or of child bearing potential not using
             a highly effective method of birth control for at least one month prior to enrolment.

         15. Sexually active males not committing to using condoms during the course of the study
             (except if their partner is not of childbearing potential).

         16. Known or suspected active alcohol or drug abuse.

         17. Bleeding risk : Known inherited predisposition to bleeding, patients who require
             full-dose anticoagulation, Patients who require full-dose antiplatelet therapy,
             History of hemorrhagic CNS event within 12 months prior to screening , Any of the
             following within 3 months prior to screening : Gross / frank haemoptysis or
             haematuria, Active gastro-intestinal bleeding or ulcers, Major injury or surgery

         18. Thrombotic risk

         19. Surgical procedures planned to occur during trial period.

         20. Coagulopathy

         21. Uncontrolled systemic arterial hypertension

         22. known hypersensitivity to lactose or any component of the study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1199.30.54002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.61005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.61003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toorak Gardens</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.61004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.61001 Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.32004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.32002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.55002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.55001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vila Clementino</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.06004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.06005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.01003 Division of Respirology</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.01002 St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.56001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Providencia</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.86005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.86003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.86004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prague 8</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Usti nad Labem</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.3306A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.3305A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.3305B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.3305C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.3304C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.3307A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nice Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris Cedex 18</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bad Berka</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Donaustauf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Freiburg/Breisgau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.30004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alexandroupolis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.30001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.30002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Larisa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.36004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deszk</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.36005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szekesfehervar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.35301 Mater Misericordiae Hospital</name>
      <address>
        <city>Dublin 7</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.39008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ascoli Piceno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.39013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Busto Arsizio (va)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.39007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.39012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.39009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.39011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.39010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.39003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gyunggido</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.52001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Distrito Federal</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.31002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.35105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.35106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.35107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.35108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.35109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.35101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.07001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.07002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.07003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.27001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bellville</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.27003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.27002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tygerberg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.88605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.88601 National Taiwan University</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.88603 Tri-service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.88606 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.88604 Chang Gung Memorial Hosp-Linkou</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.90001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.90002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.44006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.44003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.44005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.44007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1199.30.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Westbury on Trym</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>El Salvador</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2007</study_first_submitted>
  <study_first_submitted_qc>August 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2007</study_first_posted>
  <results_first_submitted>November 14, 2014</results_first_submitted>
  <results_first_submitted_qc>January 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2015</results_first_posted>
  <disposition_first_submitted>June 2, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>June 2, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 17, 2014</disposition_first_posted>
  <last_update_submitted>January 5, 2015</last_update_submitted>
  <last_update_submitted_qc>January 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2015</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Patients were treated with matching Placebo.</description>
        </group>
        <group group_id="P2">
          <title>Nintedanib 50 qd</title>
          <description>Patients were treated with 50mg nintedanib once daily</description>
        </group>
        <group group_id="P3">
          <title>Nintedanib 50 Bid</title>
          <description>Patients were treated with 50mg nintedanib twice daily</description>
        </group>
        <group group_id="P4">
          <title>Nintedanib 100 Bid</title>
          <description>Patients were treated with 100mg nintedanib twice daily</description>
        </group>
        <group group_id="P5">
          <title>Nintedanib 150 Bid</title>
          <description>Patients were treated with 150mg nintedanib twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87">Randomised</participants>
                <participants group_id="P2" count="87">Randomised</participants>
                <participants group_id="P3" count="86">Randomised</participants>
                <participants group_id="P4" count="86">Randomised</participants>
                <participants group_id="P5" count="86">Randomised</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="72"/>
                <participants group_id="P5" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason other than listed above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set: This patient set includes all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Patients were treated with matching Placebo.</description>
        </group>
        <group group_id="B2">
          <title>Nintedanib 50 qd</title>
          <description>Patients were treated with 50mg nintedanib once daily</description>
        </group>
        <group group_id="B3">
          <title>Nintedanib 50 Bid</title>
          <description>Patients were treated with 50mg nintedanib twice daily</description>
        </group>
        <group group_id="B4">
          <title>Nintedanib 100 Bid</title>
          <description>Patients were treated with 100mg nintedanib twice daily</description>
        </group>
        <group group_id="B5">
          <title>Nintedanib 150 Bid</title>
          <description>Patients were treated with 150mg nintedanib twice daily</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
            <count group_id="B2" value="86"/>
            <count group_id="B3" value="86"/>
            <count group_id="B4" value="86"/>
            <count group_id="B5" value="85"/>
            <count group_id="B6" value="428"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.8" spread="8.57"/>
                    <measurement group_id="B2" value="65.3" spread="9.42"/>
                    <measurement group_id="B3" value="64.9" spread="8.48"/>
                    <measurement group_id="B4" value="65.1" spread="8.63"/>
                    <measurement group_id="B5" value="65.4" spread="7.82"/>
                    <measurement group_id="B6" value="65.1" spread="8.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="65"/>
                    <measurement group_id="B6" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Decline in FVC</title>
        <description>Rate of decline in Forced Vital Capacity (FVC) evaluated from baseline until 52 weeks of treatment.
The means presents actually the adjusted rate based on a MMRM with fixed terms for treatment*time, gender*height, gender*age and random terms for patient effect, patient*time.</description>
        <time_frame>Baseline until 52 weeks</time_frame>
        <population>Observed Case (OC): This method was used for the replacement of missing values.
Randomised set: This patient set includes all randomised patients whether treated or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Decline in FVC</title>
          <description>Rate of decline in Forced Vital Capacity (FVC) evaluated from baseline until 52 weeks of treatment.
The means presents actually the adjusted rate based on a MMRM with fixed terms for treatment*time, gender*height, gender*age and random terms for patient effect, patient*time.</description>
          <population>Observed Case (OC): This method was used for the replacement of missing values.
Randomised set: This patient set includes all randomised patients whether treated or not.</population>
          <units>Liters/year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.190" spread="0.036"/>
                    <measurement group_id="O2" value="-0.174" spread="0.037"/>
                    <measurement group_id="O3" value="-0.210" spread="0.035"/>
                    <measurement group_id="O4" value="-0.162" spread="0.035"/>
                    <measurement group_id="O5" value="-0.060" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8530</p_value>
            <p_value_desc>The p-value presented is computed in the course of the closing testing procedure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM with fixed terms for treatment*time, gender*height, gender*age and random terms for patient effect, patient*time.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.016</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.052</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.086</ci_lower_limit>
            <ci_upper_limit>0.118</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7558</p_value>
            <p_value_desc>The p-value from the hierarchical testing procedure was calculated as a sensitivity analysis</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM with fixed terms for treatment*time, gender*height, gender*age and random terms for patient effect, patient*time.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7920</p_value>
            <p_value_desc>The p-value presented is computed in the course of the closing testing procedure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM with fixed terms for treatment*time, gender*height, gender*age and random terms for patient effect, patient*time.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.020</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.051</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.119</ci_lower_limit>
            <ci_upper_limit>0.080</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6991</p_value>
            <p_value_desc>The p-value from the hierarchical testing procedure was calculated as a sensitivity analysis</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM with fixed terms for treatment*time, gender*height, gender*age and random terms for patient effect, patient*time.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8530</p_value>
            <p_value_desc>The p-value presented is computed in the course of the closing testing procedure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM with fixed terms for treatment*time, gender*height, gender*age and random terms for patient effect, patient*time.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.028</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.051</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.071</ci_lower_limit>
            <ci_upper_limit>0.128</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5736</p_value>
            <p_value_desc>Additionally the p-value from the hierarchical testing procedure was calculated as a sensitivity analysis</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM with fixed terms for treatment*time, gender*height, gender*age and random terms for patient effect, patient*time.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0639</p_value>
            <p_value_desc>The p-value presented is computed in the course of the closing testing procedure.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM with fixed terms for treatment*time, gender*height, gender*age and random terms for patient effect, patient*time.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.131</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.027</ci_lower_limit>
            <ci_upper_limit>0.235</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0136</p_value>
            <p_value_desc>Additionally the p-value from the hierarchical testing procedure was calculated as a sensitivity analysis</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM with fixed terms for treatment*time, gender*height, gender*age and random terms for patient effect, patient*time.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in FVC%Pred</title>
        <description>Change from baseline in percentage of predicted Forced Vital Capacity (FVC%pred) at 52 weeks.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline and region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>Last Observation Carried Forward (LOCF): This method was used for the replacement of missing values.
Randomised set: This patient set includes all randomised patients whether treated or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in FVC%Pred</title>
          <description>Change from baseline in percentage of predicted Forced Vital Capacity (FVC%pred) at 52 weeks.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline and region.</description>
          <population>Last Observation Carried Forward (LOCF): This method was used for the replacement of missing values.
Randomised set: This patient set includes all randomised patients whether treated or not.</population>
          <units>percentage of predicted FVC</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.00" spread="1.019"/>
                    <measurement group_id="O2" value="-4.58" spread="1.029"/>
                    <measurement group_id="O3" value="-4.90" spread="0.984"/>
                    <measurement group_id="O4" value="-3.15" spread="1.004"/>
                    <measurement group_id="O5" value="-1.04" spread="0.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2774</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.312</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.15</ci_lower_limit>
            <ci_upper_limit>4.01</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4014</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.312</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.48</ci_lower_limit>
            <ci_upper_limit>3.68</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0314</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.324</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>5.46</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.319</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.37</ci_lower_limit>
            <ci_upper_limit>7.56</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in FVC</title>
        <description>Change from baseline in percentage of absolute Forced Vital Capacity (FVC) at 52 weeks.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline and region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in FVC</title>
          <description>Change from baseline in percentage of absolute Forced Vital Capacity (FVC) at 52 weeks.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline and region.</description>
          <population>LOCF-Randomised set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.036"/>
                    <measurement group_id="O2" value="-0.18" spread="0.036"/>
                    <measurement group_id="O3" value="-0.19" spread="0.035"/>
                    <measurement group_id="O4" value="-0.13" spread="0.035"/>
                    <measurement group_id="O5" value="-0.06" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3644</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4525</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0471</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>0.26</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change From Baseline in FVC%Pred</title>
        <description>Percent change from baseline in percentage of predicted Forced Vital Capacity (FVC%pred) at 52 weeks.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline and region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change From Baseline in FVC%Pred</title>
          <description>Percent change from baseline in percentage of predicted Forced Vital Capacity (FVC%pred) at 52 weeks.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline and region.</description>
          <population>LOCF-Randomised set</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.28" spread="1.321"/>
                    <measurement group_id="O2" value="-6.37" spread="1.334"/>
                    <measurement group_id="O3" value="-6.42" spread="1.277"/>
                    <measurement group_id="O4" value="-3.47" spread="1.302"/>
                    <measurement group_id="O5" value="-1.81" spread="1.283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5920</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.702</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.43</ci_lower_limit>
            <ci_upper_limit>4.26</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6155</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.702</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.49</ci_lower_limit>
            <ci_upper_limit>4.20</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0271</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.716</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>7.18</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.710</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.11</ci_lower_limit>
            <ci_upper_limit>8.83</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change From Baseline in FVC</title>
        <description>Percent change from baseline in absolute Forced Vital Capacity (FVC) at 52 weeks.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline and region</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change From Baseline in FVC</title>
          <description>Percent change from baseline in absolute Forced Vital Capacity (FVC) at 52 weeks.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline and region</description>
          <population>LOCF-Randomised set</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.96" spread="1.314"/>
                    <measurement group_id="O2" value="-6.98" spread="1.327"/>
                    <measurement group_id="O3" value="-7.16" spread="1.272"/>
                    <measurement group_id="O4" value="-4.13" spread="1.285"/>
                    <measurement group_id="O5" value="-2.52" spread="1.277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5601</p_value>
            <p_value_desc>ANCOVA with fixed terms for treatment, baseline, region.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.692</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.34</ci_lower_limit>
            <ci_upper_limit>4.31</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6366</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.694</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.53</ci_lower_limit>
            <ci_upper_limit>4.13</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0246</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.702</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>7.18</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.700</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.10</ci_lower_limit>
            <ci_upper_limit>8.78</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change From Baseline in FVC by Categories</title>
        <description>Change from baseline in percentage of Forced Vital Capacity (FVC) at 52 weeks in below mentioned categories:
Decrease &gt; 10% or 200mL
Change within &lt;= 10% or &lt;=200 mL
Increase &gt; 10% or 200mL</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change From Baseline in FVC by Categories</title>
          <description>Change from baseline in percentage of Forced Vital Capacity (FVC) at 52 weeks in below mentioned categories:
Decrease &gt; 10% or 200mL
Change within &lt;= 10% or &lt;=200 mL
Increase &gt; 10% or 200mL</description>
          <population>LOCF-Randomised set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease &gt; 10% or 200mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change within &lt;= 10% or &lt;=200mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase &gt; 10% or 200mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7543</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.911</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.506</ci_lower_limit>
            <ci_upper_limit>1.637</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6704</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.136</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.631</ci_lower_limit>
            <ci_upper_limit>2.045</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1649</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.657</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.363</ci_lower_limit>
            <ci_upper_limit>1.189</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0041</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.415</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.227</ci_lower_limit>
            <ci_upper_limit>0.757</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival (All Causes of Death and Lung-transplant Free)</title>
        <description>Survival (all causes of death and lung-transplant free) at 52 weeks, based on overall mortality and on-treatment survival.
Failure means participants with event and Censored means participants with no event.</description>
        <time_frame>52 weeks</time_frame>
        <population>OC-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Survival (All Causes of Death and Lung-transplant Free)</title>
          <description>Survival (all causes of death and lung-transplant free) at 52 weeks, based on overall mortality and on-treatment survival.
Failure means participants with event and Censored means participants with no event.</description>
          <population>OC-Randomised set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="83"/>
                    <measurement group_id="O4" value="82"/>
                    <measurement group_id="O5" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5882</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with fixed terms for treatment, gender, age, height, region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.278</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.526</ci_lower_limit>
            <ci_upper_limit>3.102</ci_upper_limit>
            <estimate_desc>Hazard ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0653</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with fixed terms for treatment, gender, age, height, region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.290</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.078</ci_lower_limit>
            <ci_upper_limit>1.081</ci_upper_limit>
            <estimate_desc>Hazard ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0847</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with fixed terms for treatment, gender, age, height, region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.350</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.106</ci_lower_limit>
            <ci_upper_limit>1.154</ci_upper_limit>
            <estimate_desc>Hazard ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5383</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with fixed terms for treatment, gender, age, height, region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.732</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.271</ci_lower_limit>
            <ci_upper_limit>1.977</ci_upper_limit>
            <estimate_desc>Hazard ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in SpO2 at Rest</title>
        <description>Absolute change from baseline in oxygen saturation (SpO2) at rest.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in SpO2 at Rest</title>
          <description>Absolute change from baseline in oxygen saturation (SpO2) at rest.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
          <population>LOCF-Randomised set</population>
          <units>Percentage of SpO2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" spread="0.373" lower_limit="-2.03" upper_limit="-0.56"/>
                    <measurement group_id="O2" value="-0.86" spread="0.380" lower_limit="-1.60" upper_limit="-0.11"/>
                    <measurement group_id="O3" value="-0.97" spread="0.357" lower_limit="-1.67" upper_limit="-0.27"/>
                    <measurement group_id="O4" value="0.06" spread="0.363" lower_limit="-0.65" upper_limit="0.78"/>
                    <measurement group_id="O5" value="-0.18" spread="0.360" lower_limit="-0.89" upper_limit="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3658</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.483</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4956</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.478</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0051</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.482</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>2.31</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0211</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.483</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>2.07</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in SpO2 at Rest by Categories</title>
        <description>Absolute change from baseline in oxygen saturation (SpO2) at rest by below mentioned categories:
SpO2 (non-invasive) at 52 weeks:
Decrease &gt; 4% SpO2
Change within +/- 4% SpO2
Increase &gt; 4% SpO2</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in SpO2 at Rest by Categories</title>
          <description>Absolute change from baseline in oxygen saturation (SpO2) at rest by below mentioned categories:
SpO2 (non-invasive) at 52 weeks:
Decrease &gt; 4% SpO2
Change within +/- 4% SpO2
Increase &gt; 4% SpO2</description>
          <population>LOCF-Randomised set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease &gt; 4%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0"/>
                    <measurement group_id="O2" value="4.9"/>
                    <measurement group_id="O3" value="8.1"/>
                    <measurement group_id="O4" value="6.0"/>
                    <measurement group_id="O5" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change within +/- 4%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.8"/>
                    <measurement group_id="O2" value="90.2"/>
                    <measurement group_id="O3" value="89.5"/>
                    <measurement group_id="O4" value="89.3"/>
                    <measurement group_id="O5" value="92.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase &gt; 4%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="4.9"/>
                    <measurement group_id="O3" value="2.3"/>
                    <measurement group_id="O4" value="4.8"/>
                    <measurement group_id="O5" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1021</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.428</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.155</ci_lower_limit>
            <ci_upper_limit>1.184</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4318</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.682</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.262</ci_lower_limit>
            <ci_upper_limit>1.773</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0934</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.412</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.146</ci_lower_limit>
            <ci_upper_limit>1.161</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0317</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.313</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.108</ci_lower_limit>
            <ci_upper_limit>0.903</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in PaO2</title>
        <description>Absolute change from baseline in Arterial oxygen partial pressure (PaO2) at week 52. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>OC-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in PaO2</title>
          <description>Absolute change from baseline in Arterial oxygen partial pressure (PaO2) at week 52. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
          <population>OC-Randomised set</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.69" spread="1.790"/>
                    <measurement group_id="O2" value="-2.77" spread="1.865"/>
                    <measurement group_id="O3" value="-3.00" spread="1.686"/>
                    <measurement group_id="O4" value="-1.46" spread="1.632"/>
                    <measurement group_id="O5" value="-0.76" spread="1.854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6443</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.330</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.66</ci_lower_limit>
            <ci_upper_limit>3.51</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5656</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.280</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.80</ci_lower_limit>
            <ci_upper_limit>3.18</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9181</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.240</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.18</ci_lower_limit>
            <ci_upper_limit>4.64</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6970</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.387</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.77</ci_lower_limit>
            <ci_upper_limit>5.63</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in P(A-a)O2</title>
        <description>Absolute change from baseline in Alveolo-arterial oxygen gradient (P(A-a)O2) at week 52. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>OC-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in P(A-a)O2</title>
          <description>Absolute change from baseline in Alveolo-arterial oxygen gradient (P(A-a)O2) at week 52. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
          <population>OC-Randomised set</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="1.898"/>
                    <measurement group_id="O2" value="1.27" spread="1.984"/>
                    <measurement group_id="O3" value="2.22" spread="1.773"/>
                    <measurement group_id="O4" value="1.62" spread="1.723"/>
                    <measurement group_id="O5" value="2.56" spread="1.944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9811</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.490</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.84</ci_lower_limit>
            <ci_upper_limit>4.96</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6772</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.412</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.74</ci_lower_limit>
            <ci_upper_limit>5.75</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8631</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.379</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.27</ci_lower_limit>
            <ci_upper_limit>5.09</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5942</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.523</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.62</ci_lower_limit>
            <ci_upper_limit>6.31</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in PaCO2</title>
        <description>Absolute change from baseline in Arterial carbon dioxyde partial pressure (PaCO2) at week 52. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>OC-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in PaCO2</title>
          <description>Absolute change from baseline in Arterial carbon dioxyde partial pressure (PaCO2) at week 52. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
          <population>OC-Randomised set</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.549"/>
                    <measurement group_id="O2" value="0.16" spread="0.573"/>
                    <measurement group_id="O3" value="-0.44" spread="0.517"/>
                    <measurement group_id="O4" value="-0.74" spread="0.500"/>
                    <measurement group_id="O5" value="-0.77" spread="0.569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2716</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.715</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>2.19</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7871</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.696</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.18</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8721</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.685</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.46</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8523</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.734</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.58</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in PaO2 by Categories</title>
        <description>Absolute change from baseline in Arterial oxygen partial pressure (PaO2) by below mentioned categories:
Decrease &gt; 4 mmHg
Change within +/- 4 mmHg
Increase &gt; 4 mmHg</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>OC - Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in PaO2 by Categories</title>
          <description>Absolute change from baseline in Arterial oxygen partial pressure (PaO2) by below mentioned categories:
Decrease &gt; 4 mmHg
Change within +/- 4 mmHg
Increase &gt; 4 mmHg</description>
          <population>OC - Randomised set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease &gt; 4 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="42.2"/>
                    <measurement group_id="O4" value="39.7"/>
                    <measurement group_id="O5" value="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change within +/- 4 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="21.4"/>
                    <measurement group_id="O3" value="32.8"/>
                    <measurement group_id="O4" value="30.9"/>
                    <measurement group_id="O5" value="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase &gt; 4 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="29.4"/>
                    <measurement group_id="O5" value="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7997</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.093</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.549</ci_lower_limit>
            <ci_upper_limit>2.175</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7989</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.916</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.467</ci_lower_limit>
            <ci_upper_limit>1.797</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4596</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.780</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.403</ci_lower_limit>
            <ci_upper_limit>1.508</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2548</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.665</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.330</ci_lower_limit>
            <ci_upper_limit>1.341</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in P(A-a) O2 by Categories</title>
        <description>Absolute change from baseline in Alveolo-arterial oxygen gradient (P(A-a) O2) by below mentioned categories:
Decrease &gt; 4 mmHg
Change within +/- 4 mmHg
Increase &gt; 4 mmHg</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>OC - Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in P(A-a) O2 by Categories</title>
          <description>Absolute change from baseline in Alveolo-arterial oxygen gradient (P(A-a) O2) by below mentioned categories:
Decrease &gt; 4 mmHg
Change within +/- 4 mmHg
Increase &gt; 4 mmHg</description>
          <population>OC - Randomised set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease &gt; 4 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="37.0"/>
                    <measurement group_id="O3" value="31.3"/>
                    <measurement group_id="O4" value="25.4"/>
                    <measurement group_id="O5" value="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change within +/- 4 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9"/>
                    <measurement group_id="O2" value="14.8"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="28.4"/>
                    <measurement group_id="O5" value="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase &gt; 4 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1"/>
                    <measurement group_id="O2" value="48.1"/>
                    <measurement group_id="O3" value="43.0"/>
                    <measurement group_id="O4" value="46.3"/>
                    <measurement group_id="O5" value="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8887</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.051</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.521</ci_lower_limit>
            <ci_upper_limit>2.122</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5758</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.216</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.613</ci_lower_limit>
            <ci_upper_limit>2.410</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9829</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.993</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.506</ci_lower_limit>
            <ci_upper_limit>1.949</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9375</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.972</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.476</ci_lower_limit>
            <ci_upper_limit>1.985</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in DLCO</title>
        <description>Absolute change from Baseline in Diffusing capacity of the lung for carbon monoxide (DLCO) at 52 weeks.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in DLCO</title>
          <description>Absolute change from Baseline in Diffusing capacity of the lung for carbon monoxide (DLCO) at 52 weeks.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
          <population>LOCF-Randomised set</population>
          <units>mmol.min^−1.kPa^−1</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="81"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.455" spread="0.1098"/>
                    <measurement group_id="O2" value="-0.357" spread="0.1163"/>
                    <measurement group_id="O3" value="-0.610" spread="0.1038"/>
                    <measurement group_id="O4" value="-0.535" spread="0.1035"/>
                    <measurement group_id="O5" value="-0.576" spread="0.1111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4998</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.098</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1456</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.188</ci_lower_limit>
            <ci_upper_limit>0.385</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2679</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.155</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1399</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.430</ci_lower_limit>
            <ci_upper_limit>0.120</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5678</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.080</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1400</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.355</ci_lower_limit>
            <ci_upper_limit>0.195</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4053</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.121</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1448</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.406</ci_lower_limit>
            <ci_upper_limit>0.164</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in DLCO by Categories</title>
        <description>Absolute change from baseline in Diffusing capacity of the lung for carbon monoxide (DLCO) by below mentioned categories:
Decrease &gt; 15% or &gt; 1
Change &lt;= 15% or &lt;= 1
Increase &gt; 15% or &gt; 1</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF Randomized set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in DLCO by Categories</title>
          <description>Absolute change from baseline in Diffusing capacity of the lung for carbon monoxide (DLCO) by below mentioned categories:
Decrease &gt; 15% or &gt; 1
Change &lt;= 15% or &lt;= 1
Increase &gt; 15% or &gt; 1</description>
          <population>LOCF Randomized set</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="81"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease &gt; 15% or &gt; 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3"/>
                    <measurement group_id="O2" value="38.2"/>
                    <measurement group_id="O3" value="43.8"/>
                    <measurement group_id="O4" value="35.8"/>
                    <measurement group_id="O5" value="50.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change &lt;= 15% or &lt;= 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.7"/>
                    <measurement group_id="O2" value="51.5"/>
                    <measurement group_id="O3" value="51.3"/>
                    <measurement group_id="O4" value="56.8"/>
                    <measurement group_id="O5" value="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase &gt; 15% or &gt; 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="10.3"/>
                    <measurement group_id="O3" value="5.0"/>
                    <measurement group_id="O4" value="7.4"/>
                    <measurement group_id="O5" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7307</p_value>
            <method>Regression, Logistic</method>
            <method_desc>An ordinal logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.892</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.465</ci_lower_limit>
            <ci_upper_limit>1.710</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3869</p_value>
            <method>Regression, Logistic</method>
            <method_desc>An ordinal logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.317</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.706</ci_lower_limit>
            <ci_upper_limit>2.458</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8237</p_value>
            <method>Regression, Logistic</method>
            <method_desc>An ordinal logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.931</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.498</ci_lower_limit>
            <ci_upper_limit>1.741</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1177</p_value>
            <method>Regression, Logistic</method>
            <method_desc>An ordinal logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.676</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.878</ci_lower_limit>
            <ci_upper_limit>3.202</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Distance Walk (6-MWT)</title>
        <description>Absolute change from baseline in distance walk (6-MWT) at 52 weeks. The 6-Minutes Walk Test (6-MWT) was conducted according to the American Thoracic Society (ATS) Criteria. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Distance Walk (6-MWT)</title>
          <description>Absolute change from baseline in distance walk (6-MWT) at 52 weeks. The 6-Minutes Walk Test (6-MWT) was conducted according to the American Thoracic Society (ATS) Criteria. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
          <population>LOCF-Randomised set</population>
          <units>Meter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="72"/>
                <count group_id="O5" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.67" spread="12.732"/>
                    <measurement group_id="O2" value="-46.91" spread="13.652"/>
                    <measurement group_id="O3" value="-48.84" spread="11.974"/>
                    <measurement group_id="O4" value="-36.80" spread="12.131"/>
                    <measurement group_id="O5" value="-29.35" spread="12.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5111</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-11.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>17.089</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.86</ci_lower_limit>
            <ci_upper_limit>22.37</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4176</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>16.234</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.11</ci_lower_limit>
            <ci_upper_limit>18.76</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9454</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>16.506</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.60</ci_lower_limit>
            <ci_upper_limit>31.34</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7101</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>16.980</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.08</ci_lower_limit>
            <ci_upper_limit>39.72</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Dyspnoea Rating on Borg Scale Before Exercise (6-MWT)</title>
        <description>Absolute change from baseline in Dyspnoea rating before exercise (6-MWT) at 52 weeks based on Borg scale as mentioned below :
0: Nothing at all, 0.5: Very, very slight (just noticable), 1: Very slight, 2: Slight (light), 3: Moderate, 4: Somewhat severe, 5: Severe (heavy), 6, 7:Very severe, 8, 9, 10: Very, very severe (Maximal).
The 6-Minutes Walk Test (6-MWT) was conducted according to the ATS Criteria. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Dyspnoea Rating on Borg Scale Before Exercise (6-MWT)</title>
          <description>Absolute change from baseline in Dyspnoea rating before exercise (6-MWT) at 52 weeks based on Borg scale as mentioned below :
0: Nothing at all, 0.5: Very, very slight (just noticable), 1: Very slight, 2: Slight (light), 3: Moderate, 4: Somewhat severe, 5: Severe (heavy), 6, 7:Very severe, 8, 9, 10: Very, very severe (Maximal).
The 6-Minutes Walk Test (6-MWT) was conducted according to the ATS Criteria. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
          <population>LOCF-Randomised set</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="72"/>
                <count group_id="O5" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.227" spread="0.1695"/>
                    <measurement group_id="O2" value="0.282" spread="0.1817"/>
                    <measurement group_id="O3" value="0.045" spread="0.1594"/>
                    <measurement group_id="O4" value="0.260" spread="0.1612"/>
                    <measurement group_id="O5" value="0.086" spread="0.1736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8090</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.055</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2271</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.392</ci_lower_limit>
            <ci_upper_limit>0.502</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3995</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.182</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2158</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.606</ci_lower_limit>
            <ci_upper_limit>0.242</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8822</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.033</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2193</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.399</ci_lower_limit>
            <ci_upper_limit>0.464</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5338</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.141</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2257</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.584</ci_lower_limit>
            <ci_upper_limit>0.303</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Dyspnoea Rating on Borg Scale After Exercise (6-MWT)</title>
        <description>Change from baseline in Dyspnoea rating after exercise (6-MWT) at 52 weeks based on Borg scale as mentioned below :
0: Nothing at all, 0.5: Very, very slight (just noticable), 1: Very slight, 2: Slight (light), 3: Moderate, 4: Somewhat severe, 5: Severe (heavy), 6, 7:Very severe, 8, 9, 10: Very, very severe (Maximal).
The 6-Minutes Walk Test (6-MWT) was conducted according to the ATS Criteria. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Dyspnoea Rating on Borg Scale After Exercise (6-MWT)</title>
          <description>Change from baseline in Dyspnoea rating after exercise (6-MWT) at 52 weeks based on Borg scale as mentioned below :
0: Nothing at all, 0.5: Very, very slight (just noticable), 1: Very slight, 2: Slight (light), 3: Moderate, 4: Somewhat severe, 5: Severe (heavy), 6, 7:Very severe, 8, 9, 10: Very, very severe (Maximal).
The 6-Minutes Walk Test (6-MWT) was conducted according to the ATS Criteria. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
          <population>LOCF-Randomised set</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="72"/>
                <count group_id="O5" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.527" spread="0.2439"/>
                    <measurement group_id="O2" value="0.639" spread="0.2616"/>
                    <measurement group_id="O3" value="0.449" spread="0.2295"/>
                    <measurement group_id="O4" value="0.377" spread="0.2321"/>
                    <measurement group_id="O5" value="0.194" spread="0.2492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7329</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.112</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3272</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.532</ci_lower_limit>
            <ci_upper_limit>0.755</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8009</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.078</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3109</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.690</ci_lower_limit>
            <ci_upper_limit>0.533</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6358</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.150</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3159</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.771</ci_lower_limit>
            <ci_upper_limit>0.472</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3064</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.333</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3252</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.973</ci_lower_limit>
            <ci_upper_limit>0.307</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in MRC Dyspnea Scale by Categories</title>
        <description>Absolute change from baseline in Medical Research Council (MRC) dyspnea scale by below mentioned categories:
Decrease
No Change
Increase</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF- Randomised</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in MRC Dyspnea Scale by Categories</title>
          <description>Absolute change from baseline in Medical Research Council (MRC) dyspnea scale by below mentioned categories:
Decrease
No Change
Increase</description>
          <population>LOCF- Randomised</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="82"/>
                <count group_id="O5" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="13.3"/>
                    <measurement group_id="O3" value="8.6"/>
                    <measurement group_id="O4" value="14.6"/>
                    <measurement group_id="O5" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9"/>
                    <measurement group_id="O2" value="45.3"/>
                    <measurement group_id="O3" value="53.1"/>
                    <measurement group_id="O4" value="45.1"/>
                    <measurement group_id="O5" value="53.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3"/>
                    <measurement group_id="O2" value="41.3"/>
                    <measurement group_id="O3" value="38.3"/>
                    <measurement group_id="O4" value="40.2"/>
                    <measurement group_id="O5" value="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9646</p_value>
            <method>Regression, Logistic</method>
            <method_desc>An ordinal logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.014</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.540</ci_lower_limit>
            <ci_upper_limit>1.906</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9850</p_value>
            <method>Regression, Logistic</method>
            <method_desc>An ordinal logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.994</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.536</ci_lower_limit>
            <ci_upper_limit>1.844</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7136</p_value>
            <method>Regression, Logistic</method>
            <method_desc>An ordinal logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.123</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.604</ci_lower_limit>
            <ci_upper_limit>2.089</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1705</p_value>
            <method>Regression, Logistic</method>
            <method_desc>An ordinal logistic regression model with fixed terms for treatment, baseline of corresponding continuous value, region.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.551</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.828</ci_lower_limit>
            <ci_upper_limit>2.906</ci_upper_limit>
            <estimate_desc>Odds ratio lower than 1 favours the treatment group over placebo. Negative change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in FEV1/FVC</title>
        <description>Change from baseline of percentage of FVC expelled in the first second of a forced expiration (FEV1/FVC) at 52 weeks.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in FEV1/FVC</title>
          <description>Change from baseline of percentage of FVC expelled in the first second of a forced expiration (FEV1/FVC) at 52 weeks.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
          <population>LOCF-Randomised set</population>
          <units>percentage of FVC</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.529"/>
                    <measurement group_id="O2" value="-0.10" spread="0.533"/>
                    <measurement group_id="O3" value="0.00" spread="0.511"/>
                    <measurement group_id="O4" value="-0.53" spread="0.516"/>
                    <measurement group_id="O5" value="-0.42" spread="0.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0479</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.680</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.69</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0685</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.680</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.58</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0099</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.684</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.12</ci_lower_limit>
            <ci_upper_limit>-0.43</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0152</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.683</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.01</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SGRQ Total Score</title>
        <description>Change from baseline in Saint George's Respiratory Questionnaire (SGRQ) total score. Total score is defined as sum of the three domain scores symptoms, activities and impacts. Scores range from 0 to 100, with higher scores indicating worst possible health status.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SGRQ Total Score</title>
          <description>Change from baseline in Saint George's Respiratory Questionnaire (SGRQ) total score. Total score is defined as sum of the three domain scores symptoms, activities and impacts. Scores range from 0 to 100, with higher scores indicating worst possible health status.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
          <population>LOCF-Randomised set</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="82"/>
                <count group_id="O5" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.46" spread="1.731"/>
                    <measurement group_id="O2" value="4.67" spread="1.779"/>
                    <measurement group_id="O3" value="2.18" spread="1.654"/>
                    <measurement group_id="O4" value="1.48" spread="1.660"/>
                    <measurement group_id="O5" value="-0.66" spread="1.712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7250</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.253</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.22</ci_lower_limit>
            <ci_upper_limit>3.64</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1389</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.213</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.63</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0741</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.221</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.35</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0071</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.262</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.57</ci_lower_limit>
            <ci_upper_limit>-1.67</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SGRQ Domain Score Symptoms</title>
        <description>Change from baseline in Saint George's Respiratory Questionnaire (SGRQ) domain score symptoms. Scores range from 0 to 100, with higher scores indicating more limitations.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SGRQ Domain Score Symptoms</title>
          <description>Change from baseline in Saint George's Respiratory Questionnaire (SGRQ) domain score symptoms. Scores range from 0 to 100, with higher scores indicating more limitations.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
          <population>LOCF-Randomised set</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="82"/>
                <count group_id="O5" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.45" spread="2.446"/>
                    <measurement group_id="O2" value="3.39" spread="2.514"/>
                    <measurement group_id="O3" value="2.11" spread="2.338"/>
                    <measurement group_id="O4" value="2.33" spread="2.346"/>
                    <measurement group_id="O5" value="-3.14" spread="2.403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3370</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.183</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.32</ci_lower_limit>
            <ci_upper_limit>3.20</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1659</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.126</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.49</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1897</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.138</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.29</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0028</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.184</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.86</ci_lower_limit>
            <ci_upper_limit>-3.34</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SGRQ Domain Score Impacts</title>
        <description>Change from baseline in Saint George's Respiratory Questionnaire (SGRQ) domain score impacts. Scores range from 0 to 100, with higher scores indicating worst possible health status.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF - Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SGRQ Domain Score Impacts</title>
          <description>Change from baseline in Saint George's Respiratory Questionnaire (SGRQ) domain score impacts. Scores range from 0 to 100, with higher scores indicating worst possible health status.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
          <population>LOCF - Randomised set</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="82"/>
                <count group_id="O5" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21" spread="1.986"/>
                    <measurement group_id="O2" value="3.71" spread="2.040"/>
                    <measurement group_id="O3" value="1.73" spread="1.897"/>
                    <measurement group_id="O4" value="0.79" spread="1.906"/>
                    <measurement group_id="O5" value="-0.14" spread="1.965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8458</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.586</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.59</ci_lower_limit>
            <ci_upper_limit>4.58</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3286</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.540</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.48</ci_lower_limit>
            <ci_upper_limit>2.51</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1799</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.548</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.43</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0948</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.597</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.46</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Domain Score Activities</title>
        <description>Change from baseline in Saint George's Respiratory Questionnaire (SGRQ) domain score activities. Scores range from 0 to 100, with higher scores indicating worst possible health status.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Domain Score Activities</title>
          <description>Change from baseline in Saint George's Respiratory Questionnaire (SGRQ) domain score activities. Scores range from 0 to 100, with higher scores indicating worst possible health status.
Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
          <population>LOCF-Randomised set</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="82"/>
                <count group_id="O5" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.48" spread="1.910"/>
                    <measurement group_id="O2" value="7.39" spread="1.962"/>
                    <measurement group_id="O3" value="3.54" spread="1.824"/>
                    <measurement group_id="O4" value="3.00" spread="1.832"/>
                    <measurement group_id="O5" value="0.32" spread="1.887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9708</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.484</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.98</ci_lower_limit>
            <ci_upper_limit>4.79</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1069</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.440</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.74</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0682</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.453</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.31</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0043</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.494</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.06</ci_lower_limit>
            <ci_upper_limit>-2.26</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>St George's Respiratory Questionnaire (SGRQ) Responder</title>
        <description>St George's Respiratory Questionnaire (SGRQ) responder (&lt;= -4 points change) (%) at 52 weeks-worst case</description>
        <time_frame>52 weeks</time_frame>
        <population>Worst case - Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>St George's Respiratory Questionnaire (SGRQ) Responder</title>
          <description>St George's Respiratory Questionnaire (SGRQ) responder (&lt;= -4 points change) (%) at 52 weeks-worst case</description>
          <population>Worst case - Randomised set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1"/>
                    <measurement group_id="O2" value="23.0"/>
                    <measurement group_id="O3" value="26.7"/>
                    <measurement group_id="O4" value="32.6"/>
                    <measurement group_id="O5" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2698</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on an Cochran-Mantel-Haenszel test to adjust for region effect.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>3.31</ci_upper_limit>
            <estimate_desc>In case of missing data, patient has been set to non-responder. Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0891</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on an Cochran-Mantel-Haenszel test to adjust for region effect.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>4.01</ci_upper_limit>
            <estimate_desc>In case of missing data, patient has been set to non-responder. Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0069</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on an Cochran-Mantel-Haenszel test to adjust for region effect.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.29</ci_lower_limit>
            <ci_upper_limit>5.66</ci_upper_limit>
            <estimate_desc>In case of missing data, patient has been set to non-responder. Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0341</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on an Cochran-Mantel-Haenszel test to adjust for region effect.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>4.61</ci_upper_limit>
            <estimate_desc>In case of missing data, patient has been set to non-responder. Odds ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TLC</title>
        <description>Change from Baseline in Total Lung Capacity (TLC) at 52 weeks. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TLC</title>
          <description>Change from Baseline in Total Lung Capacity (TLC) at 52 weeks. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
          <population>LOCF-Randomised set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.240" spread="0.0765"/>
                    <measurement group_id="O2" value="-0.218" spread="0.0809"/>
                    <measurement group_id="O3" value="-0.100" spread="0.0725"/>
                    <measurement group_id="O4" value="-0.082" spread="0.0723"/>
                    <measurement group_id="O5" value="0.118" spread="0.0774"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8288</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.022</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.178</ci_lower_limit>
            <ci_upper_limit>0.222</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1506</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.140</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0974</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.051</ci_lower_limit>
            <ci_upper_limit>0.332</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1059</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.158</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0977</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.034</ci_lower_limit>
            <ci_upper_limit>0.351</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.358</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1008</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.160</ci_lower_limit>
            <ci_upper_limit>0.556</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in RV</title>
        <description>Change from Baseline in Residual volume (RV) at 52 weeks. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in RV</title>
          <description>Change from Baseline in Residual volume (RV) at 52 weeks. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
          <population>LOCF-Randomised set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.036" spread="0.0512"/>
                    <measurement group_id="O2" value="-0.056" spread="0.0543"/>
                    <measurement group_id="O3" value="0.029" spread="0.0484"/>
                    <measurement group_id="O4" value="-0.012" spread="0.0484"/>
                    <measurement group_id="O5" value="0.086" spread="0.0518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7789</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.019</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0680</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.153</ci_lower_limit>
            <ci_upper_limit>0.115</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3149</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.066</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0652</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.063</ci_lower_limit>
            <ci_upper_limit>0.194</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7062</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.025</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0654</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.104</ci_lower_limit>
            <ci_upper_limit>0.153</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0703</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.123</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0675</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.010</ci_lower_limit>
            <ci_upper_limit>0.255</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Positive change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in TGV</title>
        <description>Change from Baseline in Thoracic gas volume (TGV) at 52 weeks. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in TGV</title>
          <description>Change from Baseline in Thoracic gas volume (TGV) at 52 weeks. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
          <population>LOCF-Randomised set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.137" spread="0.0657"/>
                    <measurement group_id="O2" value="-0.075" spread="0.0707"/>
                    <measurement group_id="O3" value="-0.035" spread="0.0622"/>
                    <measurement group_id="O4" value="-0.016" spread="0.0623"/>
                    <measurement group_id="O5" value="0.200" spread="0.0668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4792</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.063</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0884</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.111</ci_lower_limit>
            <ci_upper_limit>0.236</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2221</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.103</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0839</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.062</ci_lower_limit>
            <ci_upper_limit>0.268</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1510</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.121</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0843</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.044</ci_lower_limit>
            <ci_upper_limit>0.287</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.337</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0874</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.165</ci_lower_limit>
            <ci_upper_limit>0.509</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in VC</title>
        <description>Change from baseline in Vital capacity (VC) at 52 weeks. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in VC</title>
          <description>Change from baseline in Vital capacity (VC) at 52 weeks. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
          <population>LOCF-Randomised set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.191" spread="0.0458"/>
                    <measurement group_id="O2" value="-0.095" spread="0.0485"/>
                    <measurement group_id="O3" value="-0.107" spread="0.0433"/>
                    <measurement group_id="O4" value="-0.082" spread="0.0432"/>
                    <measurement group_id="O5" value="0.010" spread="0.0462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1129</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.097</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0609</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.023</ci_lower_limit>
            <ci_upper_limit>0.217</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1498</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.084</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0584</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.031</ci_lower_limit>
            <ci_upper_limit>0.199</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0632</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.109</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0585</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.006</ci_lower_limit>
            <ci_upper_limit>0.224</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.201</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0604</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.083</ci_lower_limit>
            <ci_upper_limit>0.320</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in IC</title>
        <description>Change from Baseline in Inspiratory Capacity (IC) at 52 weeks. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>LOCF-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in IC</title>
          <description>Change from Baseline in Inspiratory Capacity (IC) at 52 weeks. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region.</description>
          <population>LOCF-Randomised set</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.031" spread="0.0509"/>
                    <measurement group_id="O2" value="-0.064" spread="0.0539"/>
                    <measurement group_id="O3" value="-0.053" spread="0.0483"/>
                    <measurement group_id="O4" value="-0.038" spread="0.0479"/>
                    <measurement group_id="O5" value="-0.012" spread="0.0515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6306</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.033</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0676</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.165</ci_lower_limit>
            <ci_upper_limit>0.100</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7426</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.021</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0650</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.149</ci_lower_limit>
            <ci_upper_limit>0.106</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9209</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.006</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0651</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.134</ci_lower_limit>
            <ci_upper_limit>0.121</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7701</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with fixed terms for treatment, baseline, region.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.020</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0671</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.112</ci_lower_limit>
            <ci_upper_limit>0.152</ci_upper_limit>
            <estimate_desc>Mean difference to placebo is calculated. Negative change indicates worsening.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With at Least One IPF Exacerbation</title>
        <description>Number of patients with at least one Idiopathic Pulmonary Fibrosis (IPF) exacerbation at 52 weeks</description>
        <time_frame>52 weeks</time_frame>
        <population>OC-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With at Least One IPF Exacerbation</title>
          <description>Number of patients with at least one Idiopathic Pulmonary Fibrosis (IPF) exacerbation at 52 weeks</description>
          <population>OC-Randomised set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6671</p_value>
            <p_value_desc>Based on the statistic of ln(risk ratio) having a normal distribution N[0,[ (1/number with at least one exacerbation in Nintedanib group) + (1//number with at least one exacerbation in placebo) ] ]</p_value_desc>
            <method>Negative binomial model</method>
            <method_desc>Default log link function and adjusted for an off-set variable (logarithm of the follow-up time), for gender, height, age and region as fixed effects.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
            <estimate_desc>Risk ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5926</p_value>
            <p_value_desc>Based on the statistic of ln(risk ratio) having a normal distribution N[0,[ (1/number with at least one exacerbation in Nintedanib group) + (1//number with at least one exacerbation in placebo) ] ]</p_value_desc>
            <method>Negative binomial model</method>
            <method_desc>Default log link function and adjusted for an off-set variable (logarithm of the follow-up time), for gender, height, age and region as fixed effects.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>1.84</ci_upper_limit>
            <estimate_desc>Risk ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1381</p_value>
            <p_value_desc>Based on the statistic of ln(risk ratio) having a normal distribution N[0,[ (1/number with at least one exacerbation in Nintedanib group) + (1//number with at least one exacerbation in placebo) ] ]</p_value_desc>
            <method>Negative binomial model</method>
            <method_desc>Default log link function and adjusted for an off-set variable (logarithm of the follow-up time), for gender, height, age and region as fixed effects.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>Risk ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0150</p_value>
            <p_value_desc>Based on the statistic of ln(risk ratio) having a normal distribution N[0,[ (1/number with at least one exacerbation in Nintedanib group) + (1//number with at least one exacerbation in placebo) ] ]</p_value_desc>
            <method>Negative binomial model</method>
            <method_desc>Default log link function and adjusted for an off-set variable (logarithm of the follow-up time), for gender, height, age and region as fixed effects.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
            <estimate_desc>Risk ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrences of IPF Exacerbations Per Patient Per Year</title>
        <description>Occurrences of Idiopathic Pulmonary Fibrosis (IPF) exacerbations per patient per year at 52 weeks</description>
        <time_frame>52 weeks</time_frame>
        <population>OC-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrences of IPF Exacerbations Per Patient Per Year</title>
          <description>Occurrences of Idiopathic Pulmonary Fibrosis (IPF) exacerbations per patient per year at 52 weeks</description>
          <population>OC-Randomised set</population>
          <units>Exacerbations Per Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.243" spread="0.8008"/>
                    <measurement group_id="O2" value="0.243" spread="0.7884"/>
                    <measurement group_id="O3" value="0.242" spread="0.9830"/>
                    <measurement group_id="O4" value="0.256" spread="1.7315"/>
                    <measurement group_id="O5" value="0.075" spread="0.5177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8282</p_value>
            <method>Negative binomial model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.347</ci_lower_limit>
            <ci_upper_limit>2.336</ci_upper_limit>
            <estimate_desc>Risk ratio is actually Rate Ratio. Rate ratio is calculated based on Negative binomial model with default log link function and adjusted for an off−set variable and age, height, gender, region (all effects fixed).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5326</p_value>
            <method>Negative Binomial model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.278</ci_lower_limit>
            <ci_upper_limit>1.938</ci_upper_limit>
            <estimate_desc>Risk ratio is actually Rate Ratio. Rate ratio is calculated based on Negative binomial model with default log link function and adjusted for an off−set variable and age, height, gender, region (all effects fixed).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1944</p_value>
            <method>Negative Binomial model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.167</ci_lower_limit>
            <ci_upper_limit>1.438</ci_upper_limit>
            <estimate_desc>Risk ratio is actually Rate Ratio. Rate ratio is calculated based on Negative binomial model with default log link function and adjusted for an off−set variable and age, height, gender, region (all effects fixed).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0324</p_value>
            <method>Negative Binomial model</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.056</ci_lower_limit>
            <ci_upper_limit>0.882</ci_upper_limit>
            <estimate_desc>Risk ratio is actually Rate Ratio. Rate ratio is calculated based on Negative binomial model with default log link function and adjusted for an off−set variable and age, height, gender, region (all effects fixed).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Occurrence of IPF Exacerbation</title>
        <description>This endpoint is called time to first occurrence of IPF exacerbation however it was actually analysed as the proportion of patients having occurrence of Idiopathic Pulmonary Fibrosis (IPF) exacerbation at 52 weeks.
Failure means participants with event and Censored means participants with no event.</description>
        <time_frame>52 weeks</time_frame>
        <population>OC-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Occurrence of IPF Exacerbation</title>
          <description>This endpoint is called time to first occurrence of IPF exacerbation however it was actually analysed as the proportion of patients having occurrence of Idiopathic Pulmonary Fibrosis (IPF) exacerbation at 52 weeks.
Failure means participants with event and Censored means participants with no event.</description>
          <population>OC-Randomised set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8"/>
                    <measurement group_id="O2" value="11.5"/>
                    <measurement group_id="O3" value="11.6"/>
                    <measurement group_id="O4" value="7.0"/>
                    <measurement group_id="O5" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2"/>
                    <measurement group_id="O2" value="88.5"/>
                    <measurement group_id="O3" value="88.4"/>
                    <measurement group_id="O4" value="93.0"/>
                    <measurement group_id="O5" value="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5206</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with fixed terms for treatment, gender, age, height, region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.758</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.326</ci_lower_limit>
            <ci_upper_limit>1.765</ci_upper_limit>
            <estimate_desc>Hazard ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6862</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with fixed terms for treatment, gender, age, height, region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.841</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.362</ci_lower_limit>
            <ci_upper_limit>1.952</ci_upper_limit>
            <estimate_desc>Hazard ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1891</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with fixed terms for treatment, gender, age, height, region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.517</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.193</ci_lower_limit>
            <ci_upper_limit>1.384</ci_upper_limit>
            <estimate_desc>Hazard ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0161</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with fixed terms for treatment, gender, age, height, region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.158</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.035</ci_lower_limit>
            <ci_upper_limit>0.711</ci_upper_limit>
            <estimate_desc>Hazard ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival (Death Due to Respiratory Cause, and Lung-transplant Free)</title>
        <description>Survival (death due to respiratory cause, and lung-transplant free) at 52 weeks.
Failure means participants with event and Censored means participants with no event.</description>
        <time_frame>52 weeks</time_frame>
        <population>OC-Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Survival (Death Due to Respiratory Cause, and Lung-transplant Free)</title>
          <description>Survival (death due to respiratory cause, and lung-transplant free) at 52 weeks.
Failure means participants with event and Censored means participants with no event.</description>
          <population>OC-Randomised set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="10.3"/>
                    <measurement group_id="O3" value="3.5"/>
                    <measurement group_id="O4" value="2.3"/>
                    <measurement group_id="O5" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.8"/>
                    <measurement group_id="O2" value="89.7"/>
                    <measurement group_id="O3" value="96.5"/>
                    <measurement group_id="O4" value="97.7"/>
                    <measurement group_id="O5" value="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7449</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with fixed terms for treatment, gender, age, height, region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.173</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.448</ci_lower_limit>
            <ci_upper_limit>3.072</ci_upper_limit>
            <estimate_desc>Hazard ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0925</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with fixed terms for treatment, gender, age, height, region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.316</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.083</ci_lower_limit>
            <ci_upper_limit>1.209</ci_upper_limit>
            <estimate_desc>Hazard ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0379</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with fixed terms for treatment, gender, age, height, region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.190</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.040</ci_lower_limit>
            <ci_upper_limit>0.911</ci_upper_limit>
            <estimate_desc>Hazard ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0600</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with fixed terms for treatment, gender, age, height, region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.225</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.048</ci_lower_limit>
            <ci_upper_limit>1.065</ci_upper_limit>
            <estimate_desc>Hazard ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Time to progression. Progression was defined as at least one of the following: 5mmHg increase in the alveolo-arterial pressure difference in oxygen (P(A-a)O2), 10% decrease in FVC (FVC(baseline)-FVC(progression) &gt;= 10%) or Death.
Failure means participants with event and Censored means participants with no event.</description>
        <time_frame>52 weeks</time_frame>
        <population>OC - Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were treated with matching Placebo.</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O5">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Time to progression. Progression was defined as at least one of the following: 5mmHg increase in the alveolo-arterial pressure difference in oxygen (P(A-a)O2), 10% decrease in FVC (FVC(baseline)-FVC(progression) &gt;= 10%) or Death.
Failure means participants with event and Censored means participants with no event.</description>
          <population>OC - Randomised set</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363" lower_limit="302" upper_limit="366"/>
                    <measurement group_id="O2" value="365" lower_limit="309" upper_limit="366"/>
                    <measurement group_id="O3" value="365" lower_limit="330" upper_limit="365"/>
                    <measurement group_id="O4" value="365">The 95% CI for the median could not be calculated due to computational reason as the number of participants with event was insufficient.</measurement>
                    <measurement group_id="O5" value="365">The 95% CI for the median could not be calculated due to computational reason as the number of participants with event was insufficient.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7883</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with fixed terms for treatment, gender, age, height, region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.055</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.713</ci_lower_limit>
            <ci_upper_limit>1.563</ci_upper_limit>
            <estimate_desc>Hazard ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8293</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with fixed terms for treatment, gender, age, height, region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.958</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.646</ci_lower_limit>
            <ci_upper_limit>1.419</ci_upper_limit>
            <estimate_desc>Hazard ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3030</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with fixed terms for treatment, gender, age, height, region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.805</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.534</ci_lower_limit>
            <ci_upper_limit>1.216</ci_upper_limit>
            <estimate_desc>Hazard ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6505</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with fixed terms for treatment, gender, age, height, region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.910</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.605</ci_lower_limit>
            <ci_upper_limit>1.369</ci_upper_limit>
            <estimate_desc>Hazard ratio lower than 1 favours the treatment group over placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose Plasma Concentration of Nintedanib in Plasma at Steady State on Day 365 (Cpre,ss,365) and Day 729 (Cpre,ss,729).</title>
        <description>Cpre,ss,729 represents the pre-dose plasma concentration of nintedanib in plasma at steady state on Day 729 and Cpre,ss,365 represents the pre-dose plasma concentration of nintedanib in plasma at steady state on Day 365. At day 365, values only for Nintedanib 50 qd group are presented as no values reported for other groups and at day 729, values are presented for all group except for Nintedanib 50 qd group as no values reported for it.</description>
        <time_frame>day 365 and day 729</time_frame>
        <population>Randomised set</population>
        <group_list>
          <group group_id="O1">
            <title>Nintedanib 50 qd</title>
            <description>Patients were treated with 50mg nintedanib once daily</description>
          </group>
          <group group_id="O2">
            <title>Nintedanib 50 Bid</title>
            <description>Patients were treated with 50mg nintedanib twice daily</description>
          </group>
          <group group_id="O3">
            <title>Nintedanib 100 Bid</title>
            <description>Patients were treated with 100mg nintedanib twice daily</description>
          </group>
          <group group_id="O4">
            <title>Nintedanib 150 Bid</title>
            <description>Patients were treated with 150mg nintedanib twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose Plasma Concentration of Nintedanib in Plasma at Steady State on Day 365 (Cpre,ss,365) and Day 729 (Cpre,ss,729).</title>
          <description>Cpre,ss,729 represents the pre-dose plasma concentration of nintedanib in plasma at steady state on Day 729 and Cpre,ss,365 represents the pre-dose plasma concentration of nintedanib in plasma at steady state on Day 365. At day 365, values only for Nintedanib 50 qd group are presented as no values reported for other groups and at day 729, values are presented for all group except for Nintedanib 50 qd group as no values reported for it.</description>
          <population>Randomised set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="41.6"/>
                    <measurement group_id="O2" value="2.12" spread="91.1"/>
                    <measurement group_id="O3" value="4.20" spread="69.0"/>
                    <measurement group_id="O4" value="6.66" spread="94.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First drug administration until 14 days after last drug administration</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Patients were treated with matching Placebo.</description>
        </group>
        <group group_id="E2">
          <title>Nintedanib 50 qd</title>
          <description>Patients were treated with 50mg nintedanib once daily</description>
        </group>
        <group group_id="E3">
          <title>Nintedanib 50 Bid</title>
          <description>Patients were treated with 50mg nintedanib twice daily</description>
        </group>
        <group group_id="E4">
          <title>Nintedanib 100 Bid</title>
          <description>Patients were treated with 100mg nintedanib twice daily</description>
        </group>
        <group group_id="E5">
          <title>Nintedanib 150 Bid</title>
          <description>Patients were treated with 150mg nintedanib twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MEDDRA 13.1">Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Scleritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anti-neutrophil cytoplasmic antibody positive vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Campylobacter intestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Eye infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>PO2 decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Transplant evaluation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Myofascial pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Nephritic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Lung transplant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Prosthesis implantation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="57" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="44" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were numerous additional pre-specified endpoints. Full results are available under the BI Transparency web page ( http://trials.boehringer-ingelheim.com/trial_results.html )</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

